Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

New Cloud Platform “STB CLOUD” Disrupts AI Drug Discovery Worldwide (KOSDAQ:226330.KQ)

Syntekabio, Inc.

Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, has launched STB CLOUD worldwide. Running on Syntekabio’s own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology. It can process small molecule drug discovery on any device, anytime and anywhere. STB CLOUD outperforms common Software as a Service (SaaS) options in the market. By integrating DeepMatcher ®, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and database into the cloud system. Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources. It generates a comprehensive automatic report, including active substance candidates with users’ minimum input, for instance, only by inputting the name of the target protein related to a disease of interest. “We live in a rapidly changing world with constant disruptions by new and advanced technologies. STB CLOUD is an instant game changer for faster, easier and more accurate drug discovery. Investing in technologies like this further supports clinical trials critical for making lifesaving drugs in a timely manner,” said the CEO of Syntekabio, Jongsun Jung, Ph.D. “This landmark achievement will undoubtedly strengthen Syntekabio’s position in the competitive AI drug discovery industry. Bringing STB CLOUD to the global marketplace has been a tremendous endeavor by our exceptional scientists and engineers.” For the evaluation of automated drug discovery performance in STB CLOUD, DeepMatcher ® was used for 10 target proteins with a library of 120 million compounds available for quick purchase. The evaluation included compounds with known binding affinity as positive controls in the compound library and tracked the number of positive controls recovered during the DeepMatcher ® process, which is comprised of three steps: 3D screening, optimal pose and validation. After the first step, the average recovery rate was 31 percent among 1,000 top-ranked candidates. At the completion of the final validation step (MD simulation), the recovery rate resulted in an average of 16 percent among 200 final-ranked candidates for 10 targets. These outstanding results prove not only the power of STB CLOUD but the potential of DeepMatcher ® itself in the overall drug discovery industry. Syntekabio is already working on further strengthening STB CLOUD, with a neoantigen prediction platform (NEO-ARS™) and a multivariate biomarker prediction and discovery platform (PGM-ARS™), to be used for supporting clinical trials with a selection of patients in the near future. Additionally, the company’s new high-performance supercomputing center with 10,000 CPU/GPU computing servers is underway to be completed in the first half of 2023. For business development meetings and information about Syntekabio’s products and services, contact the New York office at +1 (212) 371-2544 or admin@syntekabiousa.com. More information about STB CLOUD is available at cloud.syntekabio.com. SyntekaBio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com. Contact Details Syntekabio USA | WMSG Sabina Lee +1 201-408-5342 wgroup@wmedical.org Company Website https://www.syntekabio.com/eng

December 16, 2022 11:00 AM Eastern Standard Time

Portugal National Funder FCT Agrees Transformative Agreement with Elsevier

Elsevier

Elsevier, a global leader in research publishing and information analytics has entered into a transformative agreement with b-on to enable continued reading access for researchers affiliated with b-on institutions and open access publishing. This is the first time Elsevier has signed a transformative agreement to support Portugal. It will benefit the member institutions with access to Elsevier's extensive collection of journals on ScienceDirect. The cost of publishing open access is covered under the terms of this agreement up to a pre-set annual cap. When publishing open access in hybrid journals, eligible corresponding authors do not have to pay an article publishing charge (APC). The new three-year contract will run until 31 st October 2024. Joana Novais, Manager of the b-on Consortium said: “This agreement lays an important stepping stone in the direction of Open Access in Portugal. It is a great honour for b-on to be able to contribute to this transition to OA by providing the authors of its member institutions the possibility to publish an annual average of 2000 OA articles in hybrid journals without incremental costs.” The b-on Consortium was founded in 2004 and represents 64 institutions, mainly higher education and research institutions across Portugal. It is managed by FCCN, a unit of FCT – Foundation for Science and Technology. William Rubens, Vice President, Elsevier said: "We are delighted to be working with the b-on Consortium to support their open access ambitions. We are thrilled to have agreed to our first Open Access agreement with them to ensure access to high-quality research and enable Portuguese researchers to publish with Elsevier, enabling them to share their findings globally." Elsevier aims to find the right solutions to meet the diverse needs of academic institutions, students, researchers, and funders worldwide while ensuring published research remains trusted and of high quality. Our approach with all customers is to understand their objectives and work with them to achieve these in an economically sustainable way while preserving the quality, integrity, and sustainability of the peer-review publishing system. For more on how Elsevier supports open access, please visit our website. About b-on B-on provides unlimited and permanent access to the full texts of thousands of scientific journals and online ebooks from some of the most important content providers, through subscriptions negotiated at national level. It started operating in March 2004 and is today a reference in access to international scientific information. It brings together higher education institutions, R&D institutions, hospitals, public institutions and private non-profit institutions. B-on currently reaches around 380.000 individuals affiliated with its 64 member institutions. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, LCUA, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Elsevier Communications, UK Andrew Davis +44 7393 242466 andrew.davis@elsevier.com Company Website https://www.elsevier.com/

December 16, 2022 08:20 AM Eastern Standard Time

Ellie Diagnostics Appoints Pat McCarthy as Chief Commercial Officer

Ellie Diagnostics

Ellie Diagnostics, the leading independent diagnostics services provider for veterinarians, today announced that Pat McCarthy has been named Chief Commercial Officer. In this new role, Mr. McCarthy will drive commercial operations and strategic initiatives across the entire organization. He has more than 25 years of experience leading commercial teams and corporate accounts business strategy with high-profile companies such as PSIvet, Pet Partners LLC and IDEXX Laboratories. “On behalf of our medical board, investors, and the entire Ellie team, we are pleased to welcome Pat to our group,” said Founder and Chief Executive Officer Mark DeCourcy. “He brings a wealth of animal health, and commercial experience to Ellie Diagnostics that will be extremely valuable as the company continues to grow, and strengthen its commercial strategy.” “I am very excited to join the Ellie Diagnostics team as CCO,” said Chief Commercial Officer Pat McCarthy. “The growth potential is astonishing, and the value of service Ellie provides veterinarians is tremendous, given its advanced laboratory technology and passionate people. I look forward to strengthening our commercial strategy, and execution for the tremendous growth that is forecasted for 2023 and beyond.” About Ellie Diagnostics Ellie Diagnostics is the fastest growing independent veterinary diagnostics company in the United States, providing innovative services to veterinarians nationwide. Ellie provides next-day lab results, complimentary shipping, pathology consultations, data protection, mobile access to orders and results and innovative laboratory reporting. Their comprehensive test menu includes routine lab testing, histopathology, cytology, microbiology, and a wide variety of specialty tests. To learn more, visit www.elliediagnostics.com. Contact Details Ellie Diagnostics Jeff Gwynn, Vice President of Marketing +1 972-619-9969 jgwynn@elliediagnostics.com

December 15, 2022 12:00 PM Eastern Standard Time

Proactive research analyst John Savin on Oxford Cannabinoid Technologies

Oxford Cannabinoid Technologies Holdings PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 15, 2022 07:30 AM Eastern Standard Time

Video

Poolbeg Pharma makes "interesting addition to existing collaboration"

Poolbeg Pharma PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 15, 2022 04:48 AM Eastern Standard Time

Video

Oxford Cannabinoid Technologies "very confident" heading into 2023

Oxford Cannabinoid Technologies Holdings PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 15, 2022 04:36 AM Eastern Standard Time

Video

Kromek Group "delighted" with new contracts

Kromek Group PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 15, 2022 04:30 AM Eastern Standard Time

Video

Judge Finds Bausch Health Spin-Off Not “Imminent;” Orders Bausch Health to Provide Advance Notice of Intent to Spin in Order to Allow Injunction Challenge

Rolnick Kramer Sadighi LLP (RKS)

Yesterday, New Jersey Chancery Court Judge Margaret Goodzeit declined to set a preliminary injunction hearing to enjoin Bausch Health Companies Inc. (“Bausch Health”) from completing its corporate spin-off of its vision care business (“Bausch + Lomb”) after Bausch Health expressly represented to the Court that it has not yet determined that the last step of the spin-off — a share dividend of its Bausch + Lomb shares — will occur. Given Bausch Health’s representation that the dividend is merely “speculative” and that there will be at least 55 days’ public notice if the dividend is going to proceed, the Court found that it was not appropriate to set an injunction hearing at this time. However, in order to protect the potential judgment creditor plaintiffs in the event Bausch Health decides to change course, the Court ordered Bausch Health to provide Rolnick Kramer Sadighi LLP (“RKS”), attorneys representing plaintiffs in the case, “at least 14 days notice of any action, vote, or decision which could result in the modification or elimination of the 55 day advance public notice...” “Although we are relieved that Bausch represented that the spin-off was not imminent and might not happen at all, we are pleased that the Court ordered Bausch to provide timely advance notice of any attempt to proceed with its ill-conceived spin-off," said Larry Rolnick of RKS. "Timely advance notice will help ensure that creditors have a meaningful opportunity to obtain an injunction," he added. The Court’s ruling means that if Bausch Health decides to complete the divestiture of its Bausch + Lomb assets through a share dividend or any other means, RKS’s clients will have a court-ordered opportunity to seek to enjoin the transaction. About RKS: Rolnick Kramer Sadighi, LLP (RKS) provides strategic litigation solutions for the investment management community. Launched in 2020, RKS is a premier securities litigation boutique dedicated to serving the investment management industry, including hedge funds, mutual funds, private equity, credit, real estate, and structured finance firms. For more information, visit RKS online: https://www.rksllp.com/. Contact Details Arielle Goren +1 212-717-5863 agoren@kivvit.com Company Website https://www.rksllp.com/

December 14, 2022 08:35 AM Eastern Standard Time

BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

BriaCell Therapeutics Corp.

Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing breast cancer mortality rate. As it stands now, breast cancer is the second most common cause of cancer death in women in the U.S. It is estimated that 43,780 people — 43,250 women and 530 men — will die from breast cancer this year alone. Globally, female breast cancer is the fifth leading cause of death. An estimated 684,996 women worldwide died from breast cancer in 2020, with metastatic breast cancer causing the vast majority of the deaths. The increasing death rate has led companies like BriaCell Therapeutics Corp. (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT) to advance research and development into therapies that could prove more effective against breast and other cancers. Focusing initially on breast cancer, BriaCell is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight the disease. Immunotherapies have become the forefront of cancer treatments because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy and may also prevent cancer recurrence. BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation (NASDAQ: INCY) to evaluate the effects of combinations of novel clinical candidates. BriaCell is currently conducting a Phase I/II clinical trial of its lead product candidate, Bria-IMT™, in combination with the immunotherapy development candidate retifanlimab, an anti-PD-1 antibody provided by Incyte, for the treatment of advanced breast cancer. Positive Clinical And Quality Of Life Data On December 8, BriaCell presented positive safety/tolerability and efficacy data from its lead product candidate – Bria-IMT™ – summarized in three poster sessions during the 2022 San Antonio Breast Cancer Symposium ® (SABCS). Summary Of The Positive Data Positive clinical data reported includes tumor shrinkage, disease control, progression-free survival, and potential long-term survival benefit in advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen. “Better quality of life” and “less pain” reported by many gravely ill advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen. Notably, many patients remained in their study longer than other prior therapies, suggesting excellent tolerability and clinical effectiveness of the Bria-IMT™ combination regimen. More positive data is expected as patients remain in the study. Treatment remained well-tolerated with no dose-limiting toxicities. The posters are summarized below and also available to view here: https://briacell.com/scientific-publications/. Mayo Clinic Professor and Principal Clinical Investigator Saranya Chumsri, M.D., stated in an audio summary of the poster: “First, this is a heavily pretreated group of end-stage metastatic breast cancer (“MBC”) patients. For many of these patients, other therapies don’t exist or cannot be tolerated.” “Bria-IMT™ does not have any theoretical cross-resistance or overlapping toxicity with other MBC treatments, which is why it is so encouraging to see responses across all MBC subtypes and a very manageable adverse event experience,” he added. Dr. William V. Williams, BriaCell’s President and CEO, also commenting on the data, said, “We are impressed with the positive clinical and quality of life data in this very difficult-to-treat patient population who have failed multiple prior treatments. We’re delighted that many patients stayed on our study longer than their last therapy, suggesting the Bria-IMT™ combination regimen is both well tolerated and clinically effective.” According to him, “these results have positive implications, both for our ongoing, randomized phase II study and for planned meetings with the U.S. Food and Drug Administration (FDA) on the design of our pivotal study. Advanced MBC remains one of the most difficult cancers to treat.” “There remains an urgent, unmet medical need to find well-tolerated and effective treatments for these gravely ill cancer patients who have only months to live and cannot tolerate the harsh side effects of other cancer treatments,” Williams concluded. Read a detailed insight into the positive clinical and quality of life data in advanced metastatic breast cancer here. BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details CORE IR investors@briacell.com Company Website https://briacell.com/

December 14, 2022 08:00 AM Eastern Standard Time

1 ... 153 154 155 156 157 ... 250